Exin Therapeutics

New Capabilities

Ran the procedure with three models, one mouse each; seizure data pending.

On October 28, Exin Therapeutics chief executive Gabriel Ocana-Santero posted an account of a Claude Sonnet 5 agent choosing one of 19 gene therapies, picking the lateral entorhinal cortex, and driving 250 nanoliters of the treatment into a live mouse's brain. A veterinarian opened the skull and kept a stop button within reach. Two days later, Ocana-Santero said two more models, GPT-6.1 Sol and Grok 4.7, had each done the same on separate mice, choosing different brain regions and different therapies.

Updated Nov 1